"New Analysis Confirms VASCEPA® Efficacy in Reducing Heart Risks at AHA 2025"

A recent analysis presented at the American Heart Association 2025 confirms that VASCEPA® effectively reduces cardiovascular disease risks, particularly among patients using aspirin for risk management.

The post hoc analysis of REDUCE-IT® revealed that icosapent ethyl significantly decreased cardiovascular (CV) events in patients at high risk, emphasizing its role alongside Aspirin.
This analysis supports the use of icosapent ethyl in conjunction with Statin therapies, particularly for patients suffering from Hypertriglyceridemia and elevated Triglyceride levels.
Amarin Corporation plc presented these findings at the American Heart Association conference, reinforcing the importance of comprehensive cardiovascular risk management in preventing Cardiovascular disease.

Por Qué Es Relevante

The findings underscore the crucial role of icosapent ethyl in enhancing cardiovascular care, particularly as guidelines evolve to integrate new therapies alongside traditional treatments like Aspirin and Statin medications.